MitoNova AI Platform
undisclosedplatform · high · Thu Apr 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Discover compounds that improve mitochondrial health for aging and aging-related diseases.
Proprietary mitochondrial science-focused artificial intelligence platform trained on years of in-house and partner testing; used to identify and prioritize compounds for biological validation.
Selected for use in Northstrive Biosciences collaboration to discover and develop therapies for obesity, type 2 diabetes, cardiometabolic conditions, cardiac diseases, and obesity.
Products using Yuva Biosciences-discovered compounds, including Y100, are described as already on the market.
Northstrive Cardiometabolic AI Development Program
preclinicaldrug program · high · Thu Apr 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes, other cardiometabolic conditions, cardiac diseases, and obesity.
Collaboration using YuvaBio's MitoNova AI platform to generate computational findings and validate biological activity with custom assays; YuvaBio grants Northstrive an exclusive worldwide license to developed technology for therapeutic products.
Northstrive Biosciences signed partnership with Yuva Biosciences on April 10, 2025.
Ovarian Aging Therapeutic Development Program
exploratoryresearch program · high · Sat Jul 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Address ovarian aging using Yuva Biosciences' mitochondrial science approach.
Therapeutic development research supported by a Southern Research Therapeutic Development Fund grant.
Received Southern Research Therapeutic Development Fund grant to address ovarian aging.
Hair Loss Treatment Targeting Mitochondrial Dysfunction
undisclosedconsumer product · medium · Mon Feb 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop or partner on a hair loss treatment that targets mitochondrial dysfunction.
Application of Yuva Biosciences-discovered mitochondrial-health compounds in a hair-loss treatment partnership.
Reported partnership alongside a $7.5m financing announcement on February 26, 2024.
Y100
undisclosedconsumer product · medium
Use a Yuva Biosciences-discovered compound to support mitochondrial health in an aesthetic or skin/hair-related product context.
Consumer-facing product using a YuvaBio-discovered compound; presented in an aesthetic medicine/start-up competition context.
Listed as a Yuva Biosciences-discovered compound already used in products on the market and presented as 'YuvaBio Y100' at IMCAS Innovation Tank 2025.
